Drugs that contain Cyclosporine

1. Drug name - CEQUA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10441630 SUN PHARM Topical formulations and uses thereof Aug, 2033

(10 years from now)

US8980839 SUN PHARM Topical aqueous nanomicellar, ophthalmic solutions and uses thereof Aug, 2033

(10 years from now)

US9937225 SUN PHARM Topical formulations and uses thereof Aug, 2033

(10 years from now)

US10918694 SUN PHARM Topical cyclosporine-containing formulations and uses thereof Feb, 2037

(14 years from now)

Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).

Dosage: SOLUTION;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.09% SOLUTION;OPHTHALMIC Prescription

2. Drug name - RESTASIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8685930 ALLERGAN Methods of providing therapeutic effects using cyclosporin components Aug, 2024

(1 year, 10 months from now)

US8648048 ALLERGAN Methods of providing therapeutic effects using cyclosporin components Aug, 2024

(1 year, 10 months from now)

US8633162 ALLERGAN Methods of providing therapeutic effects using cyclosporin components Aug, 2024

(1 year, 10 months from now)

US9248191 ALLERGAN Methods of providing therapeutic effects using cyclosporin components Aug, 2024

(1 year, 10 months from now)

US8642556 ALLERGAN Methods of providing therapeutic effects using cyclosporin components Aug, 2024

(1 year, 10 months from now)

US8629111 ALLERGAN Methods of providing therapeutic effects using cyclosporin components Aug, 2024

(1 year, 10 months from now)

US8292129 ALLERGAN Dispensing device Feb, 2031

(8 years from now)

US8561859 ALLERGAN Dispensing device Apr, 2032

(9 years from now)

US9676525 ALLERGAN Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids Feb, 2034

(11 years from now)

US9669974 ALLERGAN Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids May, 2034

(11 years from now)

Treatment: Increase tear production in patients with keratoconjunctivitis sicca (dry eye).; Increase tear production to treat patients with keratoconjunctivitis sicca (dry eye).

Dosage: EMULSION;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.05% EMULSION;OPHTHALMIC Prescription

3. Drug name - VERKAZIA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8524779 SANTEN Emulsion compositions containing quaternary ammonium compounds Jan, 2026

(3 years from now)

US7973081 SANTEN Emulsion compositions containing quaternary ammonium compounds Jan, 2026

(3 years from now)

US9220694 SANTEN Emulsion compositions containing cetalkonium chloride Jan, 2026

(3 years from now)

US9956289 SANTEN Emulsion compositions containing quaternary ammonium compounds Jan, 2026

(3 years from now)

US8298568 SANTEN Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential Nov, 2027

(5 years from now)

US9132071 SANTEN Compositions containing quaternary ammonium compounds Jun, 2029

(6 years from now)

Treatment: NA

Dosage: EMULSION;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.1% EMULSION;OPHTHALMIC Prescription

availability in other generic markets.

Click on the highlighted region to filter.